ArticleBMJ open2026
Examining the immune response of participants receiving Modified Vaccinia Ankara vaccine in Africa (MpoxVax AFRIVAC): a prospective cohort study - protocol.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMpox remains an ongoing global health concern, driven by an ongoing clade I outbreak in Central Africa, which has caused substantial morbidity and mortality. Despite deployment of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine, data on the durability of vaccine-induced immune responses remain limited, particularly in African populations, women and people with HIV, highlighting the need for context-specific immunogenicity data. METHODS AND ANALYSIS: Mpox-Vax AFRIVAC is a prospective, multicentre observational cohort study conducted in Uganda, Tanzania and the Democratic Republic of the Congo (DRC). Adults eligible for MVA-BN vaccination for mpox prevention or who received a first dose within 28 days prior to enrolment are followed for 48 weeks. Serial blood samples are collected to quantify binding antibody responses and assess their durability over time. The primary outcomes are mean geometric MVA-BN-specific antibody titres at week 48 and the rate of antibody decay from week 6 to week 48. Secondary outcomes include antibody kinetics at intermediate time points, factors associated with immune responses, breakthrough infection and vaccine safety. Analyses will use descriptive and longitudinal statistical methods to evaluate immune response trajectories and associated host factors, including HIV status, age and sex. ETHICS AND DISSEMINATION: The study is conducted in accordance with the Declaration of Helsinki, registered at the Pan African Clinical Trials Registry (PACTR202601855406764) and publications will be in accordance with the recommendations of the International Committee of Medical Journal Editors. The study has received ethical approvals in Uganda, DRC and Tanzania. Approval for Uganda has been obtained from Uganda Virus Research Institute Research and Ethics Committee (GC/127/1062) and Uganda National Council for Science and Technology (HS5575ES), for DRC from the Institutional Committee of Health ethics (UCB/CIES/PB/001/2025) and for Tanzania from the National Institute for Medical Research (NIMR/HQ/R.8a/Vol.IX/5187). TRIAL REGISTRATION NUMBER: PACTR202601855406764.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.